Background We systematically reviewed the literature to answer the following research
questions:(1) Does interleukin 6 (IL-6)(receptor) antagonist therapy reduce mortality in …

Background The prevalence of bacterial infection in patients with COVID-19 is low, however,
empiric antibiotic use is high. Risk stratification may be needed to minimize unnecessary …

Background The efficacy of interleukin-6 receptor blockade in hospitalized patients with
coronavirus disease 2019 (Covid-19) who are not receiving mechanical ventilation is …

Objectives The objective of this study was to estimate the association between tocilizumab
or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 …

Background Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in
pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients …

Background Based on current evidence, recent guidelines of the National Institute of Health,
USA indicated the use of remdesivir and dexamethasone for the treatment of COVID-19 …

Cytokine storm syndrome (CSS) is a severe complication of inflammatory immune diseases
or treatment of malignancies; it may also appear during the progression of COVID-19. CSS …

Background Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). It is currently unknown whether …

The efficacy of tocilizumab (TOC), monoclonal antibody against interleukin‐6 (IL‐6) receptor,
in patients with coronavirus disease‐2019 (COVID‐19) patients has led to conflicting results …

As the pandemic progresses, the pathophysiology of coronavirus disease 2019 (COVID‐19)
is becoming clearer and the potential for immunotherapy is increasing. However, clinical …